KIDRON Capital Assets Announces First Close of Fund Dedicated to Women's Health

KIDRON Capital Assets, the first-of-its-kind fund, has achieved its successful first close, marking a significant milestone as the premier venture capital fund dedicated to Women's Health. 

The fund targets untapped opportunities in Women's Health across Europe, the USA, and Israel. KIDRON's portfolio encompasses a diverse array of sectors, including medical devices, diagnostics, digital health, therapeutics, and services, ensuring its ability to impact various facets of women's health. 

The fund's inaugural investments are:

• Beyond Medicine: Pioneering the longevity space with cutting-edge solutions redefining human health span by targeting mitochondrial health, improving skin rejuvenation and alleviating menopausal symptoms.
• Portal: Revolutionizing a $1B market with a simplified, scalable solution for oncology clinics, backed by a proven team with six exits to giants like Medtronic and BD, Portal's approach enhances access to care and quality of life for women facing cancer, signaling strong potential for investor gains.
• Renal Guard: The only clinically validated solution to prevent Acute Kidney Injury (AKI), a risk heightened for women during cardiac surgeries. With its CE approval, initial sales and investigation in the US, Renal Guard is redefining standards of care, ensuring women's health and safety during common surgical procedures, while promising substantial returns for investors

Read the full press release here.